Vertice Pharma said Tuesday it closed its previously announced acquisition of VistaPharm. Financial terms weren’t announced. Warburg Pincus is investing up to $300 million.
NEW YORK, Dec. 22, 2015 /PRNewswire/ — Vertice Pharma, a specialty pharmaceuticals company focused on improving patients’ health, today announced it closed on the previously announced acquisition of VistaPharm, a specialized generics manufacturer of liquid and unit dosage pain medications for the hospital market, retail pharmacy and outpatient clinics. Terms of the transaction were not disclosed.
The transaction was announced on November 17th along with the formation of Vertice Pharma and its partnership with and line of equity investment of up to $300 million from Warburg Pincus, a leading global private equity firm focused on growth investing. Vertice Pharma focuses on acquiring specialty pharmaceutical companies and products, including both branded and generic products, to create a durable specialty pharmaceutical business of scale.
Don DeGolyer, Chief Executive Officer, Vertice Pharma commented, “We are excited to have acquired VistaPharm. We look forward to working with the talented team of employees and continuing to develop the high quality products that our customers and patients have come to expect.”
About Vertice Pharma
Vertice Pharma is a specialty pharmaceuticals company focused on improving patients’ health. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies. Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Jersey.
For more information visit www.verticepharma.com
Formed in 1998, VistaPharm is a Largo, Florida-based healthcare company that specializes in delivering generic pharmaceutical and OTC products for the hospital market, retail pharmacy and specialized clinical setting.